home genetic news bioinformatics biotechnology literature journals ethics positions events sitemap

UBBFriend: Email This Page to Someone!
  Biotechnical requests and sources
  AnaSpec Expands HCV NS3/4A Protease Selection

Post New Topic  Post A Reply
profile | register | preferences | faq | search

next newest topic | next oldest topic
Author Topic:   AnaSpec Expands HCV NS3/4A Protease Selection
posted 12-20-2010 09:19 PM     Click Here to See the Profile for anaspec   Click Here to Email anaspec     Edit/Delete Message Reply w/Quote
AnaSpec, Eurogentec Group is pleased to announce the expansion of our NS3/4A protease selection to include proteases from genotypes 1a, 1b, 2a, 3a and 4d. These recombinant HCV NS3/4A proteases are highly active and can be used with the SensoLyteŽ 490, 520, or 620 HCV Protease Assay Kits for screening of anti-HCV protease drugs. HCV NS3 protease is responsible for the cleavage at the NS3/NS4A, NS4A/NS4B, NS4B/NS5A, and NS5A/NS5B sites of the nonstructural protein. It is essential for viral replication and the formation of infectious viral particles, and thus has been considered as one of the most attractive targets for anti-HCV therapy.3-7

Hepatitis C Virus (HCV) belongs to the Flaviviridae family of positive, single stranded RNA. Approximately 170 million people worldwide are infected with this virus and infection results in liver diseases such as chronic hepatitis, cirrhosis and hepatocellular carcinoma.1 Seven major HCV genotypes have been identified which differ in >30 nucleotide sites.2 Genotypes 1, 2 and 3 are found predominantly in the US, Europe, Australia, Japan, Taiwan, Thailand and China; Genotype 4 in the Middle East, Egypt and Central Africa; Genotype 5 in South Africa and Genotype 6 in Southeast Asia.2

AnaSpec, Eurogentec Group also provides HCV NS3/4A mutant proteases. These mutants provide researchers with additional tools to assess the implications and explore a response to the emergence of protease inhibitor resistant NS3 proteases.


1. Seeff, LB and JH. Hoofnagle, Hepatology 36, S1 (2002).
2. Imhof, I. and P. Simmonds, J. Virol. 84, 4597 (2010).
3. Sali, DL. et al., Biochem. 37, 3392 (1998).
4. Steinkuhler, C. et al., Biochem. 37, 8899 (1998).
5. Gallinari, P. et al., J. Virol. 72, 6758 (1998).
6. Hardy, RW. et al. J. Virol. 77, 2029 (2003).
7. Hamill, P. and F. Jean, Biochem. 44, 6586 (2005).

About AnaSpec, Eurogentec Group

Since 1993, AnaSpec, Inc is a leading provider of integrated proteomics and genomics solutionsTM for worldwide life science research. As a subsidiary of Eurogentec, AnaSpec offers expertise in peptides, detection reagents, antibodies, assay kits, oligonucleotides, and qPCRs. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening and drug discovery. AnaSpec also provides premier custom services including peptide synthesis, antibody production, assay development and oligonucleotide synthesis. AnaSpec is certified to ISO 9001:2008.

For more information visit www.anaspec.com


All times are ET (US)

next newest topic | next oldest topic

Administrative Options: Close Topic | Archive/Move | Delete Topic
Post New Topic  Post A Reply
Hop to:

Contact Us | HUM-MOLGEN

Copyright by HUM-MOLGEN 1995-2017

Powered by: Ultimate Bulletin Board, Version 5.44a
© Infopop Corporation (formerly Madrona Park, Inc.), 1998 - 2000.